India · Delayed Price · Currency is INR Concord Biotech Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 153.75 billion. The enterprise value is 150.61 billion.
| Market Cap | 153.75B |
| Enterprise Value | 150.61B |
Important Dates
The next estimated earnings date is Friday, November 7, 2025.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | Sep 3, 2025 |
Share Statistics
| Current Share Class | 104.62M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 61.13% |
| Owned by Institutions (%) | 14.48% |
| Float | 26.35M |
Valuation Ratios
The trailing PE ratio is 43.18 and the forward PE ratio is 34.82.
| PE Ratio | 43.18 |
| Forward PE | 34.82 |
| PS Ratio | 12.94 |
| PB Ratio | 8.48 |
| P/TBV Ratio | 8.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 42.29 |
| EV / Sales | 12.67 |
| EV / EBITDA | 31.29 |
| EV / EBIT | 35.33 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | n/a |
| Interest Coverage | 1,231.57 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 15.94% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 7.56M |
| Profits Per Employee | 2.27M |
| Employee Count | 1,571 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Concord Biotech has paid 1.18 billion in taxes.
| Income Tax | 1.18B |
| Effective Tax Rate | 24.83% |
Stock Price Statistics
The stock price has decreased by -22.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -22.33% |
| 50-Day Moving Average | 1,600.48 |
| 200-Day Moving Average | 1,739.79 |
| Relative Strength Index (RSI) | 38.86 |
| Average Volume (20 Days) | 17,583 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 11.88 billion and earned 3.56 billion in profits. Earnings per share was 34.03.
| Revenue | 11.88B |
| Gross Profit | 7.71B |
| Operating Income | 4.27B |
| Pretax Income | 4.74B |
| Net Income | 3.56B |
| EBITDA | 4.82B |
| EBIT | 4.27B |
| Earnings Per Share (EPS) | 34.03 |
Balance Sheet
The company has 3.18 billion in cash and 29.69 million in debt, giving a net cash position of 3.15 billion.
| Cash & Cash Equivalents | 3.18B |
| Total Debt | 29.69M |
| Net Cash | 3.15B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 18.13B |
| Book Value Per Share | 173.28 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 64.92%, with operating and profit margins of 35.97% and 29.97%.
| Gross Margin | 64.92% |
| Operating Margin | 35.97% |
| Pretax Margin | 39.87% |
| Profit Margin | 29.97% |
| EBITDA Margin | 40.60% |
| EBIT Margin | 35.97% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 10.70, which amounts to a dividend yield of 0.74%.
| Dividend Per Share | 10.70 |
| Dividend Yield | 0.74% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.05% |
| Shareholder Yield | 0.69% |
| Earnings Yield | 2.32% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |